Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Astria Therapeutics, Inc.
< Previous
1
2
Next >
Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 12, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
August 12, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference
August 07, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
May 30, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
May 24, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
May 23, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 09, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
May 08, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
April 09, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
March 25, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
March 04, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
February 20, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering
January 30, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress
November 27, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
November 13, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
November 10, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
November 09, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting
November 03, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th
October 30, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering
October 11, 2023
From
Astria Therapeutics, Inc.
Via
Business Wire
Tickers
ATXS
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.